United States Ketamine Clinics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states ketamine clinics market size was valued at USD 4.22 billion in 2025 and is estimated to grow from USD 4.66 billion in 2026 to reach USD 7.70 billion by 2031, at a CAGR of 10.55% during the forecast period (2026-2031). This report is Segmented by Clinical Indication (Depression, Anxiety Disorders, PTSD, OCD, Substance Use Disorders, Chronic Pain, Other), Therapy Modality (On-Site, Online, Hybrid), and Route of Administration (Intravenous, Intramuscular, Intranasal Esketamine, Sublingual/Oral, Subcutaneous). The Market Forecasts are Provided in Terms of Value (USD).

United States Ketamine Clinics Market Trends and Insights

Rising Treatment-Resistant Depression Burden

Treatment-resistant depression remains the clearest demand anchor for the US ketamine clinics market because the condition sits inside a large treated depression population and carries high medical and social cost. Among 8.9 million medication-treated adults with MDD in the United States, 2.8 million progress to TRD, and that group accounts for USD 43.8 billion of the USD 92.7 billion yearly burden associated with medicated MDD. The severity gap is also visible in care utilization, since TRD patients recorded average hospitalization costs of USD 6,464 versus USD 1,734 for non-TRD patients and experienced depressive episodes lasting more than 1,000 days versus 452 days. This cost profile gives ketamine clinics a stronger case when they approach referral sources or payers, because the discussion is no longer limited to symptom relief and extends to avoidable hospital use and prolonged disease burden. The CDC also reported that 11.4% of U.S. adults took prescription medication for depression in 2023, with variation by region and disability status, which supports the view that untreated or poorly treated populations remain sizable across the country. As the US ketamine clinics market expands, these structural demand conditions should keep depression-led referrals elevated even as additional indications gain traction.

Rapid-Acting Alternative to Conventional Antidepressants

The US ketamine clinics market continues to benefit from the practical gap between standard oral antidepressants and the needs of patients in acute distress. Conventional antidepressants show an overall response rate of 37% and often need 4 to 6 weeks before clear clinical improvement becomes visible, which leaves a meaningful treatment window for faster-acting care. In the Phase 3 study behind the January 2025 SPRAVATO monotherapy approval, 22.5% of patients achieved remission at week 4 compared with 7.6% on placebo, and measurable symptom improvement appeared within 24 hours of the first dose. That speed matters clinically because patients with severe symptoms often cannot wait several weeks for an initial response, and it matters operationally because earlier responders can move into maintenance schedules more quickly. A 2024 study published in PMC also found large treatment effects across depression, anxiety, and PTSD at 3 months, with durable though smaller effects at 6 months and meaningful clinical improvement in 50% to 75% of participants. As a result, the US ketamine clinics market is drawing more interest from psychiatrists and primary care physicians who want options that work faster than the conventional medication cycle.

Limited Insurance Coverage for Off-Label Ketamine Therapy

Insurance asymmetry remains the most important structural brake on the US ketamine clinics market. The practical divide is clear, Spravato has a formal FDA-approved pathway that fits reimbursement structures more easily, while IV, IM, sublingual, and subcutaneous ketamine for psychiatric use are still much more exposed to self-pay economics. That split creates two parallel business models, one tied to supervised, reimbursable esketamine care and another tied to direct patient payment for off-label treatment. The result is a narrower addressable pool for operators that rely mainly on off-label formats, even when patient demand and physician interest are strong. This also shapes competitive behavior because scale operators can invest more heavily in benefit verification, prior authorization support, and contracts that reduce friction for covered patients. Until reimbursement becomes broader across formats, the US ketamine clinics market will keep growing unevenly across patient income groups, payer types, and clinic models.

Other drivers and restraints analyzed in the detailed report include:

• Growing Psychiatrist and Patient Acceptance of Interventional Psychiatry
• Expansion of Multi-Site Clinics and Hybrid Care Pathways
• Protocol Heterogeneity and Limited Long-Term Evidence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Depression accounted for 44.31% of the US ketamine clinics market share in 2025, making it the leading clinical indication and the main revenue base for current operators. The segment is supported by the scale of TRD in the United States, where 2.8 million adults develop treatment-resistant disease within the medicated MDD population. It is also supported by the broader prevalence pool, since NIMH reported that 21 million adults experienced a major depressive episode, which leaves a wide referral base for stepped-up intervention after conventional drug failure. The January 2025 SPRAVATO monotherapy approval removed a practical barrier that had previously complicated referral decisions for some psychiatrists and patients. Within the US ketamine clinics industry, this keeps depression at the center of physician referral behavior even as clinics broaden their intake across adjacent psychiatric diagnoses.

Chronic pain is projected to record the fastest growth at 11.38% CAGR from 2026 to 2031, which shows that the US ketamine clinics market is expanding beyond its original depression focus. Stanford University began a Phase 4 study in January 2025 to evaluate IV ketamine for chronic pain with comorbid depression under propofol sedation, which should add more methodologically structured evidence by late 2026. A 2025 case series in Frontiers in Pain Research also showed clinically meaningful pain reduction from low-dose ketamine combined with biopsychosocial adjunct therapies, while suggesting a pathway to lower required dosing. Anxiety disorders, PTSD, OCD, and substance use disorders still represent smaller but meaningful pools, and the 2024 PMC study supports the view that multi-indication protocols can capture needs that single-diagnosis reporting misses.

Complete Report Scope:

• By Clinical Indication
  • Depression
  • Anxiety Disorders
  • PTSD
  • OCD
  • Substance Use Disorders
  • Chronic Pain
  • Other Indications
• By Therapy Modality
  • On-Site Therapy
  • Online Therapy
  • Hybrid Therapy
• By Route of Administration
  • Intravenous
  • Intramuscular
  • Intranasal Esketamine
  • Sublingual / Oral
  • Subcutaneous

List of Companies Covered in this Report:

• Actify Neurotherapies
• Avesta Ketamine and Wellness
• Better U
• Cambridge Biotherapies
• Capitol Ketamine & Wellness
• Complete Ketamine Solutions
• Ember Health
• Hopemark Health
• Joyous
• Keta Medical Center
• Ketamine Clinics Los Angeles
• Ketamine Wellness NY
• Klarisana
• Mindbloom
• Mindful Health Solutions
• Numinus
• Nushama
• NY Ketamine Infusions
• Revitalist Clinic
• Stella Mental Health

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support